
## Igor Yavelov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8529466/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021. Rational Pharmacotherapy in Cardiology, 2022, 17, 908-915.	0.3	1
2	Persistent risk of vascular complications and efficacy of prolonged dual antiplatelet therapy after myocardial infarction. Atherothrombosis, 2022, 11, 18-28.	0.1	0
3	Anticoagulants in the treatment of superficial vein thrombosis of lower limbs: possibilities and limitations. Atherothrombosis, 2022, 11, 94-102.	0.1	0
4	Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgBT /Ove	rl <b>ock</b> 10 T	f 500 617 Td (
5	Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784314 rg	gBJ.40verl	oæk 10 Tf 50
6	The role of platelet glycoprotein IIb / IIIa inhibitors in current treatment of acute coronary syndrome. Kardiologiya, 2022, 62, 64-72.	0.3	3
7	Parenteral anticoagulants in the treatment of acute coronary syndrome: what modern clinical guidelines say. Atherothrombosis, 2022, 12, 46-58.	0.1	2
8	DIAGNOSIS AND MANAGEMENT OF PULMONARY EMBOLISM EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) CLINICAL PRACTICE GUIDELINES (2021). Eurasian Heart Journal, 2021, , 44-77.	0.2	12
9	COVID-19 from the interdisciplinary standpoint. Round table. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2849.	0.4	6
10	Prevention of cardiovascular events in patients with stable coronary artery disease: myocardial revascularization or pharmacological treatment?. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 r	g <b>&amp;T</b> 4Over	lo <b>o</b> k 10 Tf 50
11	Elderly patient with atrial fibrillation and coronary risks. Atherothrombosis, 2021, , 51-57.	0.1	0
12	Increased level of cardiac troponin I determined by a highly sensitive method: clinical significance beyond the assessment of the severity and prognosis of acute and chronic diseases. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3011.	0.4	0
13	Regional differences in cardiac mortality rates in Russia: the role of statistical features. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2928.	0.4	9
14	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Eurasian Heart Journal, 2021, , 6-59.	0.2	4
15	Thrombodynamics parameters in individuals vaccinated against SARS-CoV-2. Profilakticheskaya Meditsina, 2021, 24, 24.	0.2	6
16	COVID-19: hemostatic parameters and specifics of antithrombotic treatment. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2571.	0.4	7
17	Thrombus of left atrium and/or its appendage in nonvalvular atrial fibrillation: echocardiographic and laboratory risk factors, capabilities for prediction and correction. Atherothrombosis, 2020, , 56-70.	0.1	4
18	The role of clopidogrel in the current treatment of acute coronary syndrome. Atherothrombosis, 2020, , 72-81.	0.1	0

IGOR YAVELOV

#	Article	IF	CITATIONS
19	THROMBUS OF LEFT ATRIUM AND/OR ITS APPENDAGE IN CASE OF NONVALVULAR ATRIAL FIBRILLATION: FREQUENCY OF DETECTION AND CLINICAL RISK FACTORS. Atherothrombosis, 2020, , 68-79.	0.1	5
20	Regarding the choice of Ð2У <sub>12</sub> platelet receptor blocker in the early invasive approach to acute coronary syndrome treatment in patients without indications for long-term anticoagulant use. Atherothrombosis, 2020, , 66-74.	0.1	0
21	COMPARATIVE CHARACTERISTICS OF MULTIMORBIDITY, DRUG TREATMENT AND OUTCOMES IN POSTSTROKE PATIENTS WITH ATRIAL FIBRILLATION AND WITH OR WITHOUT HISTORY OF MYOCARDIAL INFARCTION (REGISTRY REGION DATA). Atherothrombosis, 2020, , 56-67.	0.1	2
22	Apixaban in non-valvular atrial fibrillation and treatment of venous thromboembolism: universal safety advantage in different categories of patients. Meditsinskiy Sovet, 2020, , 48-54.	0.1	0
23	Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 99-106.	0.4	4
24	The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology, 2015, 191, 256-264.	0.8	125